MedTrace Logo

Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders

NCT00996931 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2013-05-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if lenalidomide (Revlimid®)reduces proinflammatory cytokines including TNF-alpha and may actually alter the clinical course of autism for some children.

Conditions

Interventions

DRUG

lenalidomide

2.5 mgs per day orally for 12 weeks

Sponsors & Collaborators

  • Sutter Medical Foundation

    lead OTHER

Principal Investigators

  • Michael Chez, MD · Sutter Medical Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00996931 on ClinicalTrials.gov